Versor Investments LP grew its stake in shares of Maximus, Inc. (NYSE:MMS - Free Report) by 213.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,500 shares of the health services provider's stock after purchasing an additional 5,789 shares during the period. Versor Investments LP's holdings in Maximus were worth $792,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of MMS. Vanguard Group Inc. grew its position in Maximus by 2.4% during the first quarter. Vanguard Group Inc. now owns 6,208,839 shares of the health services provider's stock valued at $520,922,000 after purchasing an additional 145,983 shares in the last quarter. Janus Henderson Group PLC boosted its stake in shares of Maximus by 2.1% during the 1st quarter. Janus Henderson Group PLC now owns 1,254,536 shares of the health services provider's stock valued at $105,255,000 after buying an additional 25,825 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Maximus by 7.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,153,977 shares of the health services provider's stock valued at $98,904,000 after acquiring an additional 79,092 shares in the last quarter. Van Berkom & Associates Inc. increased its stake in shares of Maximus by 0.8% in the second quarter. Van Berkom & Associates Inc. now owns 1,146,524 shares of the health services provider's stock worth $98,257,000 after acquiring an additional 8,811 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Maximus by 277.0% during the third quarter. Assenagon Asset Management S.A. now owns 878,894 shares of the health services provider's stock worth $81,878,000 after acquiring an additional 645,760 shares in the last quarter. Institutional investors and hedge funds own 97.21% of the company's stock.
Insider Buying and Selling
In other news, insider Michelle F. Link sold 1,363 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $92.56, for a total value of $126,159.28. Following the sale, the insider now directly owns 6,567 shares of the company's stock, valued at approximately $607,841.52. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.40% of the company's stock.
Maximus Stock Down 0.8 %
NYSE MMS traded down $0.69 on Wednesday, reaching $89.85. The stock had a trading volume of 158,506 shares, compared to its average volume of 354,921. The company has a current ratio of 1.59, a quick ratio of 1.59 and a debt-to-equity ratio of 0.61. Maximus, Inc. has a 1 year low of $76.42 and a 1 year high of $93.97. The business has a 50 day moving average price of $89.38 and a 200 day moving average price of $88.18. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of 19.06 and a beta of 0.77.
Maximus Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Saturday, November 30th. Investors of record on Friday, November 15th will be paid a $0.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.20 dividend on an annualized basis and a yield of 1.34%. Maximus's payout ratio is presently 25.16%.
Maximus Company Profile
(
Free Report)
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
Read More
Before you consider Maximus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.
While Maximus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.